Please Wait.....
Report
China Alzheimer'S Disease Therapeutics & Diagnostics Market Forecast 2024-2032
Market Report I 2024-11-27 I 135 Pages I Inkwood Research
KEY FINDINGS
The China Alzheimer's disease therapeutics & diagnostics market is anticipated to prosper at a CAGR of 6.49% over the forecast period of 2024-2032. The market was valued at $528.90 million in 2023 and is expected to reach a revenue of $935.68 million by 2032.
MARKET INSIGHTS
The China Alzheimer's disease therapeutics & diagnostics industry is experiencing a prominent rise in the number of Alzheimer's disease cases. As dementia becomes more prevalent, early diagnosis and timely treatment are increasingly vital. This growing health concern is driving the demand for advanced diagnostic tools and therapeutic solutions. Public awareness around Alzheimer's is also rising, further emphasizing the need for effective strategies to address this growing healthcare challenge.
Advancements in diagnostic technologies are playing a crucial role in transforming the China Alzheimer's disease therapeutics & diagnostics industry. Innovations such as brain imaging and biomarker testing are improving the accuracy and reliability of early-stage Alzheimer's detection. These developments not only support more precise diagnoses but also help track the progression of the disease, enabling better-informed treatment decisions.
Additionally, the number of drugs under development for Alzheimer's disease is expanding, reflecting increased investment in research and clinical trials. Pharmaceutical companies in China are working on novel therapies and exploring new drug classes to address the needs of Alzheimer's patients. This rise in drug development offers the potential for more effective treatments and improved management of the disease in the near future.
The growing elderly population in China is another key factor contributing to the market's expansion. With longer life expectancies, a larger segment of the population is reaching ages where Alzheimer's and other neurodegenerative diseases are more common. This demographic shift presents challenges but also offers opportunities for the healthcare sector to meet the needs of an aging population, fueling demand for Alzheimer's-related treatments and diagnostics.
However, notable challenges are hindering the market's progress. A major issue is the limited availability of surrogate markers for Alzheimer's disease. The development of reliable biomarkers is essential for early diagnosis, but their availability and validation are still insufficient. This limits the ability to detect the disease in its earliest stages and delays the implementation of effective treatments.
Furthermore, late-stage drug failures pose a significant obstacle in the market. Many promising drug candidates do not succeed in the later stages of clinical trials, slowing the development of effective treatments. These setbacks increase the financial risks for pharmaceutical companies and prolong the time it takes for new therapies to reach patients. Strict government regulations on drug approval and clinical trials also increase complexity, making the process of bringing new treatments to market more time-consuming and challenging. Despite the challenges, continued advancements in diagnostics and drug development hold promise for improving the management of Alzheimer's disease in China.
SEGMENTATION ANALYSIS
The China Alzheimer's disease therapeutics & diagnostics market segmentation includes the market by product. The product segment is further divided into therapeutics (including cholinesterase inhibitors, NMDA receptor antagonists, and other therapeutics) as well as diagnostics (including brain imaging, CSF test for Alzheimer's disease, and other diagnostics).
The cerebrospinal fluid (CSF) test for Alzheimer's disease has gained importance due to its ability to provide an accurate diagnosis, especially in the early stages of the disease. It involves the collection of CSF through a lumbar puncture, which is then analyzed for specific biomarkers associated with Alzheimer's, such as low amyloid-beta levels and high tau protein levels. This diagnostic method complements other techniques, like brain imaging, offering a more comprehensive approach to detecting Alzheimer's. While it is highly effective, the procedure's invasive nature and the need for specialized medical facilities may limit its widespread use.
Looking ahead, the CSF test is evolving with ongoing research aimed at improving its sensitivity and accessibility. This progress holds strong prospects for early detection and better management of Alzheimer's disease, particularly as the demand for more reliable and non-invasive diagnostic tools increases. By offering clearer insights into the biological processes of Alzheimer's, the CSF test plays a crucial role in shaping the future of Alzheimer's diagnostics in China and beyond.
COMPETITIVE INSIGHTS
Some of the eminent companies operating in the China Alzheimer's disease therapeutics & diagnostics market include Biogen Inc, Eli Lilly and Company, F Hoffmann-La Roche AG, etc.
F Hoffmann-La Roche AG, headquartered in Basel, Switzerland, is a leading global healthcare company with a strong focus on Alzheimer's disease. Roche is dedicated to developing innovative therapies for neurodegenerative conditions, including Alzheimer's. Its research efforts are centered around targeted treatments and diagnostics to improve early detection and disease management. The company's advancements in biomarker testing and clinical trials are contributing to the development of more effective Alzheimer's therapies.
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.4.1. IMPACT OF COVID-19 ON THE CHINA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
2.5. MAJOR MARKET FINDINGS
2.5.1. GROWING R&D INVESTMENT IN THE BIOMARKERS FOR EARLY DETECTION OF DEMENTIA
2.5.2. INCREASING DEMAND FOR THE PERSONALIZED MEDICINES
3. MARKET DYNAMICS
3.1. PARENT MARKET ANALYSIS
3.2. KEY DRIVERS
3.2.1. INCREASE IN ALZHEIMER'S DISEASE CASES
3.2.2. ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES
3.2.3. GROWTH IN THE NUMBER OF DRUGS UNDER DEVELOPMENT
3.2.4. EXPANSION OF THE ELDERLY POPULATION
3.3. KEY RESTRAINTS
3.3.1. LIMITED AVAILABILITY OF SURROGATE MARKERS
3.3.2. LATE-STAGE DRUG FAILURES
3.3.3. STRICT GOVERNMENT REGULATIONS
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.1.1. ADVANCEMENTS IN IN-VITRO DIAGNOSTIC TECHNIQUES
4.1.2. USAGE OF COMPUTED TOMOGRAPHY IN THE DIAGNOSTICS OF ALZHEIMER'S DISEASE
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1. BUYERS POWER
4.2.2. SUPPLIERS POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING
4.3.1. GROWTH PROSPECT MAPPING FOR CHINA
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS
4.6. VALUE CHAIN ANALYSIS
4.6.1. R&D
4.6.2. RAW MATERIAL
4.6.3. MANUFACTURING
4.6.4. WHOLESALERS/DISTRIBUTORS/RETAILERS
4.6.5. END-USER
4.7. KEY BUYING CRITERIA
4.7.1. PRICE
4.7.2. EFFICIENCY
4.7.3. SAFETY
4.8. ETYMOLOGY OF THE CHINA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
4.9. PHASES AND STERNNESS OF ALZHEIMER'S DISEASE
5. MARKET BY PRODUCT
5.1. THERAPEUTICS
5.1.1. CHOLINESTERASE INHIBITORS
5.1.2. NMDA RECEPTOR ANTAGONISTS
5.1.3. OTHER THERAPEUTICS
5.2. DIAGNOSTICS
5.2.1. BRAIN IMAGING
5.2.2. CSF TEST FOR ALZHEIMER'S DISEASE
5.2.3. OTHER DIAGNOSTICS
6. COMPETITIVE LANDSCAPE
6.1. KEY STRATEGIC DEVELOPMENTS
6.1.1. MERGERS & ACQUISITIONS
6.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
6.1.3. PARTNERSHIPS & AGREEMENTS
6.1.4. BUSINESS EXPANSIONS & DIVESTITURES
6.2. COMPANY PROFILES
6.2.1. BIOGEN INC
6.2.1.1. COMPANY OVERVIEW
6.2.1.2. PRODUCT LIST
6.2.1.3. STRENGTHS & CHALLENGES
6.2.2. ELI LILLY AND COMPANY
6.2.2.1. COMPANY OVERVIEW
6.2.2.2. PRODUCT LIST
6.2.2.3. STRENGTHS & CHALLENGES
6.2.3. F HOFFMANN-LA ROCHE AG
6.2.3.1. COMPANY OVERVIEW
6.2.3.2. PRODUCT LIST
6.2.3.3. STRENGTHS & CHALLENGES
6.2.4. NOVARTIS AG
6.2.4.1. COMPANY OVERVIEW
6.2.4.2. PRODUCTS LIST
6.2.4.3. STRENGTHS & CHALLENGES
6.2.5. JOHNSON & JOHNSON
6.2.5.1. COMPANY OVERVIEW
6.2.5.2. PRODUCT LIST
6.2.5.3. STRENGTHS & CHALLENGES
6.2.6. MERCK & CO INC
6.2.6.1. COMPANY OVERVIEW
6.2.6.2. PRODUCT LIST
6.2.6.3. STRENGTHS & CHALLENGES
6.2.7. PFIZER INC
6.2.7.1. COMPANY OVERVIEW
6.2.7.2. PRODUCT LIST
6.2.7.3. STRENGTHS & CHALLENGES
LIST OF TABLES
TABLE 1: MARKET SNAPSHOT - ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS
TABLE 2: CHINA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET REGULATORY FRAMEWORK
TABLE 3: CHINA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY PRODUCT, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 4: CHINA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY PRODUCT, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 5: KEY PLAYERS OPERATING IN CHINA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET
TABLE 6: LIST OF MERGERS & ACQUISITIONS
TABLE 7: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 8: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 9: LIST OF BUSINESS EXPANSIONS & DIVESTITURES
LIST OF FIGURES
FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
FIGURE 3: GROWTH PROSPECT MAPPING FOR CHINA
FIGURE 4: MARKET MATURITY ANALYSIS
FIGURE 5: MARKET CONCENTRATION ANALYSIS
FIGURE 6: VALUE CHAIN ANALYSIS
FIGURE 7: KEY BUYING CRITERIA
FIGURE 8: CHINA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2023
FIGURE 9: CHINA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS, 2024-2032 (IN $ MILLION)
FIGURE 10: CHINA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY THERAPEUTICS, IN 2023
FIGURE 11: CHINA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY CHOLINESTERASE INHIBITORS, 2024-2032 (IN $ MILLION)
FIGURE 12: CHINA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY NMDA RECEPTOR ANTAGONISTS, 2024-2032 (IN $ MILLION)
FIGURE 13: CHINA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY OTHER THERAPEUTICS, 2024-2032 (IN $ MILLION)
FIGURE 14: CHINA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2024-2032 (IN $ MILLION)
FIGURE 15: CHINA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY DIAGNOSTICS, IN 2023
FIGURE 16: CHINA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY BRAIN IMAGING, 2024-2032 (IN $ MILLION)
FIGURE 17: CHINA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY CSF TEST FOR ALZHEIMER'S DISEASE, 2024-2032 (IN $ MILLION)
FIGURE 18: CHINA ALZHEIMER'S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2024-2032 (IN $ MILLION)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security